Literature DB >> 26448661

Netupitant/Palonosetron.

Dennis J Cada1, James Leonard2, Danial E Baker3.   

Abstract

Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation/medication use evaluation (DUE/MUE) is also provided each month. With a subscription, the monographs are sent in print and are also available on-line. Monographs can be customized to meet the needs of a facility. A drug class review is now published monthly with The Formulary Monograph Service. Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. For more information about The Formulary Monograph Service, call The Formulary at 800-322-4349. The April 2015 monograph topics are edoxaban, diclofenac sodium injectable, olaparib, antihemophilic factor porcine, and blinatumomab. The Safety MUE is on edoxaban.

Entities:  

Year:  2015        PMID： 26448661      PMCID： PMC4589884          DOI： 10.1310/hpj5004-310

Source DB:  PubMed          Journal:  Hosp Pharm        ISSN： 0018-5787


  12 in total

Review 1.  Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference.

Authors:  F Roila; J Herrstedt; M Aapro; R J Gralla; L H Einhorn; E Ballatori; E Bria; R A Clark-Snow; B T Espersen; P Feyer; S M Grunberg; P J Hesketh; K Jordan; M G Kris; E Maranzano; A Molassiotis; G Morrow; I Olver; B L Rapoport; C Rittenberg; M Saito; M Tonato; D Warr
Journal:  Ann Oncol       Date:  2010-05       Impact factor: 32.976

Review 2.  Chemotherapy-induced nausea and vomiting.

Authors:  Paul J Hesketh
Journal:  N Engl J Med       Date:  2008-06-05       Impact factor: 91.245

3.  In vitro and in vivo pharmacological characterization of the novel NK₁ receptor selective antagonist Netupitant.

Authors:  Anna Rizzi; Barbara Campi; Valeria Camarda; Stefano Molinari; Sergio Cantoreggi; Domenico Regoli; Claudio Pietra; Girolamo Calo'
Journal:  Peptides       Date:  2012-06-23       Impact factor: 3.750

4.  Inhibition of substance P-mediated responses in NG108-15 cells by netupitant and palonosetron exhibit synergistic effects.

Authors:  Marigo Stathis; Claudio Pietra; Camilo Rojas; Barbara S Slusher
Journal:  Eur J Pharmacol       Date:  2012-06-07       Impact factor: 4.432

5.  Effect of netupitant, a highly selective NK₁ receptor antagonist, on the pharmacokinetics of palonosetron and impact of the fixed dose combination of netupitant and palonosetron when coadministered with ketoconazole, rifampicin, and oral contraceptives.

Authors:  Selma Calcagnile; Corinna Lanzarotti; Giorgia Rossi; Anders Henriksson; Klaus Peter Kammerer; Wolfgang Timmer
Journal:  Support Care Cancer       Date:  2013-06-11       Impact factor: 3.603

6.  Efficacy and safety of repeated dosing of netupitant, a neurokinin-1 receptor antagonist, in treating overactive bladder.

Authors:  F Haab; B Braticevici; G Krivoborodov; M Palmas; M Zufferli Russo; C Pietra
Journal:  Neurourol Urodyn       Date:  2013-06-14       Impact factor: 2.696

7.  Effect of netupitant, a highly selective NK₁ receptor antagonist, on the pharmacokinetics of midazolam, erythromycin, and dexamethasone.

Authors:  Corinna Lanzarotti; Giorgia Rossi
Journal:  Support Care Cancer       Date:  2013-06-01       Impact factor: 3.603

8.  Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose-ranging pivotal study.

Authors:  P J Hesketh; G Rossi; G Rizzi; M Palmas; A Alyasova; I Bondarenko; A Lisyanskaya; R J Gralla
Journal:  Ann Oncol       Date:  2014-03-07       Impact factor: 32.976

9.  Netupitant PET imaging and ADME studies in humans.

Authors:  Tulla Spinelli; Selma Calcagnile; Claudio Giuliano; Giorgia Rossi; Corinna Lanzarotti; Stuart Mair; Lloyd Stevens; Ian Nisbet
Journal:  J Clin Pharmacol       Date:  2013-11-08       Impact factor: 3.126

10.  A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy.

Authors:  M Aapro; H Rugo; G Rossi; G Rizzi; M E Borroni; I Bondarenko; T Sarosiek; C Oprean; S Cardona-Huerta; V Lorusso; M Karthaus; L Schwartzberg; S Grunberg
Journal:  Ann Oncol       Date:  2014-03-05       Impact factor: 32.976
View more
  2 in total

1.  Improving Nausea and Vomiting Post-Elipse Balloon: a Novel Single-Dose Regimen of 300 mg Netupitant/0.5 mg Palonosetron Hydrochloride.

Authors:  R Ienca; C Giardiello; A Scozzarro; R Schiano di Cola; N Di Lorenzo; Girish Juneja; G Lopez; F Badiuddin
Journal:  Obes Surg       Date:  2019-09       Impact factor: 4.129

Review 2.  Management of acute and delayed chemotherapy-induced nausea and vomiting: role of netupitant-palonosetron combination.

Authors:  Piotr K Janicki
Journal:  Ther Clin Risk Manag       Date:  2016-05-02       Impact factor: 2.423
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.